Search 

O2h has a track record of investing in emerging biotech, small molecule and frontier life science starts-ups

A passion for entrepreneurship and life sciences motivates o2h to participate in syndicated seed stage investments. O2h are ready to support the investments with active or passive support to further the objectives of the company.

Comprising 10 investment professionals, Omnes Capital’s venture capital team acquires minority stakes in young companies with high growth potential. Its main areas of interest are financing innovative business ventures in the information technology and life sciences sectors (drug development, diagnostics, medical devices, bioproduction).

For 12 years, Omnes Capital has managed FCPI mutual funds (French regulated mutual funds investing in innovative companies).

ORIGIMM is a young, ambitious Austrian biotech company striving to become a market leader in the treatment of acute and chronic infectious diseases, and dermatological conditions associated with various pathogens.

ORIGIMM is developing the worldwide first therapeutic vaccine for treatment of acne vulgaris; the disease with enormous market potential, afflicting 85% of teenagers and more than 20% of adults below 40 years of age.

Using its proprietary ProVaDis® technology platform ORIGIMM overcomes the challenges in vaccine and immune therapy development by early focus on protective efficacy of antigens in the context of human disease. This translates into a rapid selection of best, most protective candidates with a significantly improved success in clinical trials. ProVaDis platform enables ORIGIMM to rapidly build its product portfolio in many other lucrative areas.

Pfizer Venture Investments (PVI) is the corporate venture capital arm of Pfizer and was founded in 2004. PVI has an annual investments budget of $50 million and invests up to $10M per investing round. The firm focuses mainly on U.S. startups but has global reach. PVI attempts to allocate 80% of its funding to U.S. based companies and utilizes the remaining 20% for international ventures. PVI provides equity funding for private companies in need of seed, growth, or venture financing. Remaining opportunistic, PVI focuses entirely on high growth prospects in all sectors and all phases of development. The ideal candidate has a potential for high growth and returns. Additionally, PVI will seek to in-license products and buyout companies if the opportunity arises.

Pharmatek is a contract development & manufacturing company providing dosage form development & cGMP manufacturing of oral, injectable & topical products. Founded in 1999, our services focus on the rapid advancement of small molecule & peptide drug candidates from the bench to the clinic & include:

·         Formulation & Analytical Development

·         cGMP Manufacturing

·         Clinical Packaging, Labeling & Worldwide Distribution

Our experience includes first-in-man strategies, solutions for poorly soluble compounds, controlled release formulations & separate facilities for the handling of cytotoxic & potent compounds.  Pharmatek’s drug delivery technologies include:

·         Solid Dispersions

·         Particle Size Reduction

·         Lipid Delivery

·         Complexation

·         Lyophilization

·         Suspensions & Emulsions

Pharmatek’s 68,000 sq. ft. facility includes 9 class 100,000 cGMP manufacturing suites, formulation & analytical laboratories, & ICH stability storage.  Pharmatek has over 150 clients globally, ranging from virtual to large pharmaceutical companies. Having manufactured product for clinical trials in the North America, Europe & Asia; Pharmatek has successfully completed several large pharma quality, EH&S & QP audits.

Prize4Life is a non-profit organization founded in 2006 in Cambridge, MA focused on accelerating therapy development for amyotrophic lateral sclerosis (ALS, aka Lou Gehrig's disease). Prize4Life uses incentive prizes to attract new minds and drive innovation in ALS drug development. The organization is running the $1M Avi Kremer ALS Treatment Prize4Life challenge for preclinical validation of a novel ALS therapeutic in an ALS mouse model, and submissions to this prize will be accepted until June 6th 2015. In addition to prizes, Prize4Life also runs infrastructure programs to support the ALS research community, such as the ALS FORUM, an online portal of cutting edge research and drug development news in ALS (www.researchals.org).

RiverVest Venture Partners is a venture capital firm that was founded in 2000 and is based in St. Louis, Missouri with additional office in Cleveland, Ohio. The firm currently has managed over $208 million of total assets. RiverVest has raised two investment funds with total committed capital of $165 million since inception. The recent fund closed at $75 million. RiverVest typically makes equity investments into global companies, and has no specific geographic preferences. The firm will consider making investments at all the stages, and focuses on investments in seed, early-stage and select later-stage companies. The typical investment size is around $6 million, though the firm can invest more or less, depending on the opportunity. 

RiverVest is extremely opportunistic when it comes to investments in the life sciences space; with that being said RiverVests specified sectors and sub sectors of interest may or may not be an area in which RiverVest is currently looking to allocate capital to. The firm invests in companies in the biotech therapeutics and diagnostics, as well the medical technology space. 

Some of the firms investments have included companies developing biotech therapeutics and diagnostics targeting diseases of the blood and blood forming organs, neoplasms, cancer, and oncology, skin and subcutaneous tissue, cardiovascular diseases, diseases of the ear, and infectious diseases. The firm has also invested in companies developing anti-body based therapeutics. The firm has also invested in firms developing medical technologies such as therapeutic radiation devices, active implantable devices, non active implantable devices, hospital hardware, and imaging devices.